Compare CFFI & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFI | DTIL |
|---|---|---|
| Founded | 1927 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 194.3M |
| IPO Year | 1996 | 2019 |
| Metric | CFFI | DTIL |
|---|---|---|
| Price | $74.38 | $7.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 2.1K | ★ 186.6K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 37.94 | N/A |
| EPS | ★ 8.29 | N/A |
| Revenue | $140,841,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.94 | ★ N/A |
| Revenue Growth | ★ 10.63 | N/A |
| 52 Week Low | $58.00 | $3.53 |
| 52 Week High | $80.99 | $8.82 |
| Indicator | CFFI | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.10 | 63.56 |
| Support Level | $66.92 | $4.56 |
| Resistance Level | $79.57 | $8.82 |
| Average True Range (ATR) | 1.32 | 0.52 |
| MACD | -0.35 | -0.01 |
| Stochastic Oscillator | 30.97 | 79.41 |
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).